TG Therapeutics Rides MS Treatment Momentum to Fast 500 Ranking

NEW YORK, NY – November 19, 2025

Biotech’s Breakout Year

TG Therapeutics has cemented its position as a rising force in the biopharmaceutical sector, ranking #27 on the 2025 Deloitte Technology Fast 500 list. This recognition underscores a period of rapid growth driven by the commercial success of BRIUMVI (ublituximab-xiiy), its treatment for relapsing forms of multiple sclerosis (RMS). While the company previously topped the list in 2024, maintaining a high ranking in consecutive years speaks to sustained momentum in a competitive landscape. The Fast 500 ranking is based on revenue growth between fiscal years 2021 and 2024, demonstrating the transformative impact of BRIUMVI on TG Therapeutics’ financial performance.

BRIUMVI’s Impact on the Bottom Line

Since its FDA approval in December 2022, BRIUMVI has rapidly gained traction in the RMS treatment market. Initial sales figures were promising, but the last three quarters have shown consistent upward revision. Q3 2025 net sales reached $152.9 million, marking a 10% increase from the previous quarter and indicating sustained demand. Analysts attribute this success to several factors, including BRIUMVI’s efficacy, a more manageable infusion time compared to some competitors, and a competitive price point. “The growth story is particularly impressive when you consider the competitive pressure in the MS market,” noted one financial analyst. “BRIUMVI has carved out a solid niche for itself.” TG Therapeutics has capitalized on this momentum, consistently surpassing analyst expectations and raising its revenue guidance throughout 2025. This financial performance has not only fueled the company’s growth but also attracted investor attention.

Navigating a Competitive MS Landscape

The multiple sclerosis treatment market is crowded with established players and innovative new therapies. Roche’s Ocrevus remains a dominant force, and Novartis’s Kesimpta is also a significant competitor. Emerging therapies, including those targeting different mechanisms of action, are adding to the competitive intensity. TG Therapeutics is differentiating itself through BRIUMVI’s unique characteristics. The treatment’s glycoengineering allows for effective B-cell depletion at lower doses, potentially minimizing side effects. “The subcutaneous formulation currently under development could be a real game-changer,” explained a healthcare industry expert. “It would significantly enhance patient convenience and further differentiate BRIUMVI from intravenous therapies.” However, maintaining a competitive edge requires ongoing innovation and strategic investment in research and development. The firm's exploration into new indications for BRIUMVI and cell therapies for autoimmune diseases indicates a long-term commitment to advancing treatment options.

Beyond BRIUMVI: Future Growth Potential

While BRIUMVI is currently the primary revenue driver, TG Therapeutics is actively pursuing a broader pipeline of therapies. The company is advancing the development of a simplified intravenous dosing schedule for BRIUMVI, with anticipated results in mid-2026. This enhancement could further improve patient convenience and compliance. Additionally, they’re focused on the development of a subcutaneous formulation, which could be a significant differentiator in the market. Furthermore, the development of azer-cel, a cell therapy for severe autoimmune diseases, suggests an ambition to expand beyond MS. “TG Therapeutics isn't just a one-product company,” commented a biotech investor. “They're building a diversified pipeline with the potential to address multiple autoimmune conditions.” This strategic focus on innovation is crucial for sustaining long-term growth and maximizing shareholder value. Analysts see a significant upside potential for the stock, with price targets ranging from $45 to over $60. The recent announcement of a $100 million share repurchase program signals confidence in the company’s financial strength and commitment to delivering shareholder returns.